Compare Aptiv PLC (APTV) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aptiv PLC vs Viatris Inc — how do they compare? Aptiv PLC trades at $50.01 (market cap $10.34B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc is the larger of the two by market cap, and Viatris Inc pays a 2.95% dividend while Aptiv PLC pays none. Which is the better fit depends on your goals.
| APTV | VTRS | |
|---|---|---|
Market Cap | $10.34B | $18.69B |
Sector | Consumer Cyclical | Health |
52-Week High | $76.82 | $17.86 |
52-Week Low | $46.30 | $9.49 |
Enterprise Value | $15.27B | $30.81B |
Dividend Yield | — | 2.95% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aptiv PLC
Aptiv's signal and power solutions segment supplies components and systems that make up a vehicle's electrical system backbone, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The advanced safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, advanced driver-assist technologies, and displays, as well as the development of software for these systems. Aptiv's largest customer is General Motors at roughly 12% of 2021 revenue, including sales to GM's Shanghai joint venture, followed by Stellantis at 11%, and Volkswagen at 9%. North America and Europe represented approximately 38% and 33% of total 2019 revenue, respectively.
Read more on APTV →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
